Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Resectable stage I to III non-small-cell lung cancer, drawn from the whole corpus: 124 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether adjuvant immunotherapy adds anything after neoadjuvant treatment and surgery, especially for complete pathological responders, has not been tested directly.
Circulating tumour DNA after surgery identifies high-risk patients but no trial yet shows that acting on it improves survival.
About a fifth of patients given neoadjuvant therapy never reach surgery, from progression, toxicity or decline.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Screening uptake is low in most countries, so most lung cancers are still found late.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 33 changes by month →When this page itself was last checked or edited.
At the final analysis (median follow-up 38.
Eighteen-month event-free survival 70.
Median event-free survival not estimable against 15.
A milestone in how this cancer is treated.
Perioperative NSCLC (KEYNOTE-671)